<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/6B581582-43F1-426D-966F-C7451654D9B2"><gtr:id>6B581582-43F1-426D-966F-C7451654D9B2</gtr:id><gtr:name>Omeros Corporation</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Infection Immunity and Inflammation</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/6B581582-43F1-426D-966F-C7451654D9B2"><gtr:id>6B581582-43F1-426D-966F-C7451654D9B2</gtr:id><gtr:name>Omeros Corporation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/801F3019-88AB-4A46-98EB-E90FBC781DBE"><gtr:id>801F3019-88AB-4A46-98EB-E90FBC781DBE</gtr:id><gtr:firstName>Nilesh</gtr:firstName><gtr:otherNames>Jayantilal</gtr:otherNames><gtr:surname>Samani</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E3FF04F3-296B-4065-AC0D-AEC75CA301D9"><gtr:id>E3FF04F3-296B-4065-AC0D-AEC75CA301D9</gtr:id><gtr:firstName>Wilhelm</gtr:firstName><gtr:surname>Schwaeble</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EA8C975A-0C94-4BCE-82DA-19D4FA26832D"><gtr:id>EA8C975A-0C94-4BCE-82DA-19D4FA26832D</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Stephen</gtr:otherNames><gtr:surname>Marber</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0700859"><gtr:id>FEB3736A-8A9E-4349-A259-2CF973C721C2</gtr:id><gtr:title>The role of the lectin pathway of complement activation in cardiac ischemia-reperfusion injury</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700859</gtr:grantReference><gtr:abstractText>The amount of injury caused by heart attacks is the main determinant of outcome and survival. The size of the artery that is blocked and how quickly it is opened again after the onset of the heart attack is an important factor in determining the amount of injury. However, it is now clear that another form of injury also occurs, paradoxically at the time when the blood supply is restored. This is called ischaemia-reperfusion injury. The precise cause of this type of injury is not known although there is evidence that activation of a system in the blood called the complement system by a pathway called the lectin pathway plays a role. We have developed a unique model to investigate the role of this pathway in ischaemia-reperfusion injury. The proposed studies will provide definitive information on the importance of this pathway in causing ischaemia-reperfusion injury and whether inhibiting this system would be valuable way of protecting the heart after heart attacks.</gtr:abstractText><gtr:technicalSummary>The purpose of this application is to clarify the role of a protein known as MASP-2 in myocardial ischaemia reperfusion injury. MASP-2 is the key component of the only recently discovered lectin pathway of complement activation. A number of circumstantial observations indicate the Lectin pathway maybe invovled in ischaemia reperfusion injury. Within this application we will use a number of unique and novel reagents to build on our preliminary data. These agents will categorically determine the contribution of the Lectin pathway and MASP-2 to myocardial infarction and post-infarction remodelling.</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>399981</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Omeros Corporation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Development of therapeutic antibodies to limit inflammatory tissue loss in ischaemic disease</gtr:description><gtr:id>61DD1CF0-62FA-45C4-ABA4-D0E1F4598CE6</gtr:id><gtr:impact>This research has led to a series of international patents and a major scientific publication, which is currently under review</gtr:impact><gtr:partnerContribution>My partner has provided support in the development of therapeutic tools to translate my research into clinical applications and secured and financed international patents to secure the resulting IP of my research for the University of Leicester.</gtr:partnerContribution><gtr:piContribution>My team has established the proof of principle that MASP-2, a component of the lectin activation pathway of complement, can selectively be targeted to dramatically reduce tissue loss and organ function loss resulting from a devastating lectin pathway dependent post-ischaemic inflammatory condition, called ischaemia/reperfusion injury.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>596628</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant (The role of the lectin pathway of complement activation in pneumococcal infection)</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0801952</gtr:fundingRef><gtr:id>48A7B36E-3635-4AF1-80F7-2906D5741BAE</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The patent describes a technology used to inhibit the lectin activation pathway of complement and its application in treating ischaemic pathologies applying this technology as an effective therapeutic approach limiting morbidity and mortality.</gtr:description><gtr:id>C58329B8-1DFF-4356-99D2-C9190E575355</gtr:id><gtr:impact>This discovery has a wide ranging implication on all pathologies and clinical procedures involving ischaemic conditions, including organ transplantation.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2007117996</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The product is a therapeutic recombinant monoclonal antibody</gtr:description><gtr:id>9FC26D31-F758-44FE-AA63-EE25BB2E34A4</gtr:id><gtr:impact>This product will provide a novel and effective therapeutic tool in the treatment of ischaemia/reperfusion injury.</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Therapeutic inhibitors of MASP-2 functional activity</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed species specific MASP-2 inhibitors from a phage display technology platform based on a library expressing recombinant human immunoglobulins that can applied therapeutically under in vivo conditions.</gtr:description><gtr:id>4D9D70B5-9E6A-435B-95FD-A09B4EAE0A17</gtr:id><gtr:impact>The availability of potent therapeutic inhibitors of MASP-2 functional activity makes it possible to transiently inhibit the lectin activation pathway of complement and reduce the impact of ischaemia/reperfusion injury in the course of ischaemic pathologies, such as myocardial infarction.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Therapeutic inhibitors of MASP-2 functional activity</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/645D4273-06FB-4610-AC73-DC2D0871D5AB"><gtr:id>645D4273-06FB-4610-AC73-DC2D0871D5AB</gtr:id><gtr:title>Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8a9fb862836aff6b321abf7065703c03"><gtr:id>8a9fb862836aff6b321abf7065703c03</gtr:id><gtr:otherNames>Fuchs A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/060FC241-5CCA-4CCE-A796-6723F2F33F1C"><gtr:id>060FC241-5CCA-4CCE-A796-6723F2F33F1C</gtr:id><gtr:title>Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7ff09c7595c7f1b1582e2a909a1edfa8"><gtr:id>7ff09c7595c7f1b1582e2a909a1edfa8</gtr:id><gtr:otherNames>Freeley SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A23E860F-5731-488E-9983-910548EFDEEC"><gtr:id>A23E860F-5731-488E-9983-910548EFDEEC</gtr:id><gtr:title>Absence of the lectin activation pathway of complement does not increase susceptibility to Pseudomonas aeruginosa infections.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/113f27bc076d0f4fca8693aaecb9378a"><gtr:id>113f27bc076d0f4fca8693aaecb9378a</gtr:id><gtr:otherNames>Kenawy HI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C959086D-F53B-405D-89C7-BD5AA1C2B205"><gtr:id>C959086D-F53B-405D-89C7-BD5AA1C2B205</gtr:id><gtr:title>Complement research in the 18th-21st centuries: Progress comes with new technology.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce19e5acd9833452a471e3210c802621"><gtr:id>ce19e5acd9833452a471e3210c802621</gtr:id><gtr:otherNames>Sim RB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB5BB3C4-3F25-44F6-AFEF-073055FE271D"><gtr:id>BB5BB3C4-3F25-44F6-AFEF-073055FE271D</gtr:id><gtr:title>Mannan binding lectin-associated serine protease-2 (MASP-2) critically contributes to post-ischemic brain injury independent of MASP-1.</gtr:title><gtr:parentPublicationTitle>Journal of neuroinflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/420d9246bd711121f1d543c57f2ab34c"><gtr:id>420d9246bd711121f1d543c57f2ab34c</gtr:id><gtr:otherNames>Orsini F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1742-2094</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/778FDCAD-D99A-40E2-B8C0-2DDFCD7E69E9"><gtr:id>778FDCAD-D99A-40E2-B8C0-2DDFCD7E69E9</gtr:id><gtr:title>Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7aae6a1a3df68fe1d70019244cfd7d96"><gtr:id>7aae6a1a3df68fe1d70019244cfd7d96</gtr:id><gtr:otherNames>Yaseen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FD9D04D9-8FB0-4AF5-AE1C-6695AD75099D"><gtr:id>FD9D04D9-8FB0-4AF5-AE1C-6695AD75099D</gtr:id><gtr:title>Collectin-11 detects stress-induced L-fucose pattern to trigger renal epithelial injury.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f41571013db636d13570fa10eaf335ba"><gtr:id>f41571013db636d13570fa10eaf335ba</gtr:id><gtr:otherNames>Farrar CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9FD2C258-E589-4B30-AD59-089B51E9E64B"><gtr:id>9FD2C258-E589-4B30-AD59-089B51E9E64B</gtr:id><gtr:title>Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c6856aa066a730da9d045725584a65ea"><gtr:id>c6856aa066a730da9d045725584a65ea</gtr:id><gtr:otherNames>Schwaeble WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700859</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>